Adverse Event Management

The FDA has granted avasopasem a priority review for severe oral mucositis in patients with head and neck cancer who are receiving radiotherapy.

According to Fennec Pharmaceuticals, the National Comprehensive Cancer Network is updating it guidelines to recommend injections of sodium thiosulfate to reduce the risk of ototoxicity in pediatric patients receiving cisplatin.

Pediatric cancer survivors who received anthracycline-based chemotherapy may derive long-term cardio-protection from dexrazoxane.

As the therapy continues to evolve, best nursing practices become more nuanced.

A study in the Oncology Nursing Forum highlights which factors are associated with positive psychology and symptom burden in colorectal cancer survivors.

First-line ibrutinib plus prednisone missed the primary endpoint in the phase 3 iNTEGRATE trial by not improving the response rate in patients with chronic graft-versus-host-disease compared with placebo plus prednisone.

Heather Jackson, PhD, FNP-BC, NEA-BC, FAANP, provides a case-based perspective on the benefit of auricular acupuncture as a tool for managing cancer pain.

The American Society of Clinical Oncology (ASCO) has updated its guidelines providing recommendations for the management of cancer pain with opioids.

Findings showed that Black patients were 4.3 percentage points less likely to receive any opioid and 3.1 percentage points less likely to receive long-acting opioids near end-of-life compared with White patients.

Cannabidiol oil may be useful in helping patients with breast cancer manage tamoxifen-related adverse effects.

Caressa Valdueza, MSN, AGNP-BC, AOCNP, discusses toxicity management with unfolding treatment options in melanoma.

Patients with breast cancer may be at risk for more intense cognitive impairment following treatment with chemotherapy plus endocrine therapy.

Patients with early-stage, HER2-positive breast cancer who received both adjuvant ado-trastuzumab emtansine and concurrent radiotherapy did not experience a significant drop in ejection fraction or global longitudinal strain.

Black mulberry extract may help patients manage oral mucositis, dry mouth, and weight gain, while receiving oral cancer medications.

An ASCO/SIO expert panel outlined evidence supporting integrative therapies for adults. There is insufficient evidence in the pediatric population.

APRNs developed a discharge program which reduced readmission rates for patients receiving immunotherapy for advanced melanoma.

CAR T-cell therapy represents a viable treatment option for many patients, but there are potentially serious adverse events.

Adolescents and young adults who have cancer also have a negative body image, financial toxicity, and concerns about family planning.

As the treatment paradigm continues to evolve, nurses play a key role in educating patients, monitoring treatments, and watching for adverse effects.

Treatment with chemotherapy, including taxane-based chemotherapies, in the adjuvant setting did not yield significant differences in breast-cancer related lymphedema risk.

An observational study of 2450 patients with stage III colon cancer identified key factors that may increase a patient’s risk of oxaliplatin-induced peripheral neuropathy.

Patients who receive high cumulative doses of triple intrathecal therapy may be at an increased risk of neurocognitive problems.

Immunotherapy has changed the face of cancer treatment, but requires appropriate irAE management to reach full potential.

During the International Kidney Cancer Symposium, Kiran Virdee, RN, BSN, CCRN-K, outlined best practices in kidney cancer symptom management.

The rate of severe radiation dermatitis was reduced with the use of Mepital Film in patients with breast cancer undergoing mastectomy.

Following CAR T-cell therapy, the onset of hypophosphatemia may represent a biomarker for immune effector cell–associated neurotoxicity syndrome incidence and severity.

Sri Kota, MSN, BA, RN, OCN, unpacks data from the phase 3 TROPiCS-02 trial and highlights what nurses should know about sacituzumab govitecan for patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Olaparib is an oral drug manufactured in 150-mg and 100-mg tablets. Olaparib is taken by mouth, twice daily. It can be taken without or without food.

HER2-directed antibody-drug conjugates (ADCs) play an important role in the treatment of breast and gastric cancer.

An analysis of patient-reported outcomes showed that patients with advanced ovarian cancer experienced fewer abdominal or gastrointestinal toxicities with mirvetuximab soravtansine than with chemotherapy.